Güngör Özge, Yeral Sena, Özcan Büşra, Arıcan Duygu, Şimşir Ilgın Yıldırım, Akın Haluk, Aykut Ayça, Durmaz Asude
Department of Medical Genetics, Ege University School of Medicine, Izmir, Türkiye.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Gaziantep City Hospital, Gaziantep, Türkiye.
Hormones (Athens). 2025 Apr 18. doi: 10.1007/s42000-025-00659-x.
Generalized glucocorticoid resistance (GGCR) is caused by variants in the NR3C1 gene, which encodes the human glucocorticoid receptor (hGR). To date, 39 pathogenic variants of NR3C1 have been reported, primarily in the ligand-binding domain (LBD). This study presents a novel case of the NR3C1 variant located in the N-terminal domain (NTD) of hGR, highlighting its clinical and molecular significance in glucocorticoid resistance.
The patient was a 21-year-old woman presenting with chronic fatigue, irregular menstrual cycles, and osteopenia, though without any clinical signs of Cushing's syndrome. She underwent a standard evaluation of the hypothalamic-pituitary-adrenal (HPA) axis. Endocrinological tests revealed elevated levels of ACTH, morning serum cortisol, aldosterone, DHEAS, 11-deoxycortisol, pregnenolone, and corticosterone, as well as increased urinary-free cortisol excretion. The low-dose dexamethasone suppression test (LDDST) showed suppression of cortisol levels. Molecular analysis via Whole Exome Sequencing (WES) identified a novel heterozygous pathogenic variant, c.220 C > T (p.Gln74Ter), in the NR3C1 gene. This confirmed the diagnosis of glucocorticoid resistance syndrome.
This case contributes to expanding the mutational spectrum of NR3C1 in glucocorticoid resistance syndrome, supporting more accurate diagnosis and genetic counseling for affected individuals.
全身性糖皮质激素抵抗(GGCR)由NR3C1基因变异引起,该基因编码人类糖皮质激素受体(hGR)。迄今为止,已报道了39种NR3C1致病变异,主要位于配体结合域(LBD)。本研究报告了1例位于hGR N端结构域(NTD)的NR3C1变异新病例,强调了其在糖皮质激素抵抗中的临床和分子意义。
患者为一名21岁女性,有慢性疲劳、月经周期不规律和骨质减少症状,但无库欣综合征的任何临床体征。她接受了下丘脑-垂体-肾上腺(HPA)轴的标准评估。内分泌检查显示促肾上腺皮质激素(ACTH)、早晨血清皮质醇、醛固酮、硫酸脱氢表雄酮(DHEAS)、11-脱氧皮质醇、孕烯醇酮和皮质酮水平升高,尿游离皮质醇排泄增加。小剂量地塞米松抑制试验(LDDST)显示皮质醇水平受到抑制。通过全外显子组测序(WES)进行的分子分析在NR3C1基因中鉴定出一种新的杂合致病变异,即c.220 C>T(p.Gln74Ter)。这证实了糖皮质激素抵抗综合征的诊断。
该病例有助于扩大糖皮质激素抵抗综合征中NR3C1的突变谱,为受影响个体的更准确诊断和遗传咨询提供支持。